about
Charge variants in IgG1: Isolation, characterization, in vitro binding properties and pharmacokinetics in ratsPosttranslational Modifications and the Immunogenicity of BiotherapeuticsBiocontrol and Rapid Detection of Food-Borne Pathogens Using Bacteriophages and EndolysinsAdvanced protein formulationsStability engineering of the human antibody repertoireDo not drop: mechanical shock in vials causes cavitation, protein aggregation, and particle formation.The Production of a Stable Infliximab Powder: The Evaluation of Spray and Freeze-Drying for ProductionThe Structural Basis of Antibody-Antigen RecognitionThe Fab conformations in the solution structure of human immunoglobulin G4 (IgG4) restrict access to its Fc region: implications for functional activityProtein compatibility of selected cross-linking reactions for hydrogels.Distinct aggregation mechanisms of monoclonal antibody under thermal and freeze-thaw stresses revealed by hydrogen exchange.High-throughput analysis of concentration-dependent antibody self-association.High-throughput biophysical analysis and data visualization of conformational stability of an IgG1 monoclonal antibody after deglycosylation.Affinity capture mass spectrometry of biomarker proteins using peptide ligands from biopanning.Dynamic fluctuations of protein-carbohydrate interactions promote protein aggregation.Buffer-dependent fragmentation of a humanized full-length monoclonal antibody.Glycosylation of therapeutic proteins: an effective strategy to optimize efficacyResolving the micro-heterogeneity and structural integrity of monoclonal antibodies by hybrid mass spectrometric approachesFluorescent-magnetic-biotargeting multifunctional nanobioprobes for detecting and isolating multiple types of tumor cellsAggregation of a multidomain protein: a coagulation mechanism governs aggregation of a model IgG1 antibody under weak thermal stressTherapeutic protein aggregation: mechanisms, design, and control.Mass spectrometric analysis of intact human monoclonal antibody aggregates fractionated by size-exclusion chromatography.An intravaginal ring for the sustained delivery of antibodies.A graphene-based physiometer array for the analysis of single biological cells.Strategies to stabilize compact folding and minimize aggregation of antibody-based fragmentsArginine and the Hofmeister Series: the role of ion-ion interactions in protein aggregation suppression.Analysis of monoclonal antibody by a novel CE-UV/MALDI-MS interface.The solution structures of two human IgG1 antibodies show conformational stability and accommodate their C1q and FcγR ligands.Effect of formulation on the stability and aerosol performance of a nebulized antibodyAnalytical characterization of ch14.18: a mouse-human chimeric disialoganglioside-specific therapeutic antibody.Efficient In Vitro and In Vivo Activity of Glyco-Engineered Plant-Produced Rabies Monoclonal Antibodies E559 and 62-71-3.Identifying protein aggregation mechanisms and quantifying aggregation rates from combined monomer depletion and continuous scatteringAlleviating nonlinear behavior of disulfide isoforms in the reversed-phase liquid chromatography of IgG2.Functional assessment of antibody oxidation by native mass spectrometry.Surrogate target cells expressing surface anti-idiotype antibody for the clinical evaluation of an internalizing CD22-specific antibody.Time-Dependent Structural Alteration of Rituximab Analyzed by LC/TOF-MS after a Systemic Administration to Rats.Application of cyclodextrins in antibody microparticles: potentials for antibody protection in spray drying.IgG Fab fragments forming bivalent complexes by a conformational mechanism that is reversible by osmolytes.Extrinsic fluorescent dyes as tools for protein characterizationDevelopment of dextran nanoparticles for stabilizing delicate proteins
P2860
Q24619854-27B96CA9-22B0-493D-8203-EBBB992822C4Q26748614-3E56E430-6BD5-4125-B7A0-E1A21C7A99C9Q26752523-79B309BC-F8E6-4564-AF40-8279C825A294Q26822616-A19376F7-CE1E-4FC5-B9BB-5611B8210162Q26859495-4D67F7A7-9F41-4362-A71F-8BF7E74C47C4Q27333791-2D0E1532-8621-4424-B863-C60A4BE26AB4Q28554493-69DBAEEB-D687-4286-B861-807070E8B7C4Q28972262-27ED975B-4707-4AA9-ABAC-F9BC9A2AC83DQ30363006-E51581CA-9778-48AA-8DFF-B0AB4985835AQ30368683-D09E78AD-943C-479A-A667-070F2427F180Q30454017-DB29C530-0003-4311-90B3-E9F519482A8DQ30462680-F5530A1D-9A3C-4F65-938B-7A906DA59D74Q30675226-CCA02606-460D-4C15-9CCB-378E8A1632E3Q33477529-B2FF8934-5B35-46C8-BFA1-D48580FDF198Q33520919-586BF63D-A464-43E8-8F0B-D8E841DBB948Q33525646-977506D6-819D-4CD5-87C7-6629E6F41698Q33586660-132DB1BC-2785-4567-8A73-2DD0AE25A492Q33641917-5AAA9E68-FF8E-4F5F-9C7D-E2715FC7ED7DQ33798318-C4D65526-1486-495A-B04A-1CFA9EBD566EQ33834215-7367F744-BC72-415E-9FCF-839DAE05B2FBQ34097620-E269D696-F721-4F98-A4CF-DC0084A020CAQ34127391-BF3D1CD5-F490-41AB-9FD6-613D9713D1D0Q34389166-84C55DB5-06C7-4FC9-9560-038AE6CB64B7Q34431484-041E24DF-8753-420D-AB08-165D3959410BQ35018813-D9406F45-28C2-47F7-ACDA-4583C767E26FQ35033038-DD461944-DE73-4437-AE14-B5D18670FB08Q35214543-EEB75CBC-79E7-43A8-B065-BF56203391F3Q35221593-D444FAB8-65BD-4E73-A319-99132D08FD78Q35526961-B903DF4D-5908-43CF-8D95-C222AE2CA75BQ35918866-1E8B36E3-42AC-4023-99A4-EEF6E0D3B6A5Q36079932-D9BFAE7C-C2CA-4E6F-A363-7D2C659D4CEEQ36100648-1E39E57F-B1C7-4812-8F2D-373B2EE1A473Q36161091-41D83241-857B-4A35-833E-4DA4C47EAFA6Q36213342-E4821098-2605-4002-8470-EFA5F461B988Q36216376-D92BC4A9-A7D3-4D1D-B6F0-1082AD1B9FD2Q36239584-D51B9C60-33AF-4942-8501-9D4B8476D06EQ36301885-74249C2E-75DD-43DE-A3CD-DD951EBA6A74Q36466773-66EAA5ED-D7E8-4115-97C0-001A1421463CQ36738230-76AD655A-F5E0-45FB-81E8-52425F180725Q36849488-B2E03E4F-1717-4BA6-AFA5-9047DCD7F320
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Antibody structure, instability, and formulation.
@ast
Antibody structure, instability, and formulation.
@en
type
label
Antibody structure, instability, and formulation.
@ast
Antibody structure, instability, and formulation.
@en
prefLabel
Antibody structure, instability, and formulation.
@ast
Antibody structure, instability, and formulation.
@en
P2093
P356
P1476
Antibody structure, instability, and formulation.
@en
P2093
David L Zeng
Kevin King
Sandeep Nema
Satish Singh
P356
10.1002/JPS.20727
P407
P577
2007-01-01T00:00:00Z